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Abstract
Mutationally activated RAS proteins are critical oncogenic drivers in nearly 30% of all human 
cancers. As with mutant RAS, the role of wild type RAS proteins in oncogenesis, tumour 
maintenance and metastasis is context-dependent. Complexity is introduced by the existence of 
multiple RAS genes (HRAS, KRAS, NRAS) and protein "isoforms" (KRAS4A, KRAS4B), by the 
ever more complicated network of RAS signaling, and by the increasing identification of 
numerous genetic aberrations in cancers that do and do not harbour mutant RAS. Numerous 
mouse model carcinogenesis studies and examination of patient tumours reveal that, in RAS-
mutant cancers, wild type RAS proteins are likely to serve as tumour suppressors when the mutant 
RAS is of the same isoform. This evidence is particularly robust in KRAS mutant cancers, which 
often display suppression or loss of wild type KRAS, but is not as strong for NRAS. In contrast, 
although not yet fully elucidated, the preponderance of evidence indicates that wild type RAS 
proteins play a tumour promoting role when the mutant RAS is of a different isoform. In non-RAS 
mutant cancers, wild type RAS is recognized as a mediator of oncogenic signaling due to chronic 
activation of upstream receptor tyrosine kinases that feed through RAS. Additionally, in the 
absence of mutant RAS, activation of wild type RAS may drive cancer upon the loss of negative 
RAS regulators such as NF1 GAP or SPRY proteins. Here we explore the current state of 
knowledge with respect to the roles of wild type RAS proteins in human cancers.
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1. Introduction
Due in part to the prevalence of oncogenically activating mutations in RAS, it has often been 
assumed that wild type RAS alleles do not contribute significantly to RAS-mediated 
oncogenesis or tumour maintenance. Several factors have revealed this assumption to be 
overly simplistic and rendered it demonstrably false. First, both mouse model chemical 
carcinogenesis studies and the development of genetically engineered mouse models of 
cancer driven by mutationally activated RAS alleles have focused attention on the roles of 
the wild type counterparts in the presence of mutant RAS proteins (e.g., wild type KRAS in 
the presence of mutant KRAS). Second, renewed attention is now being paid to the fact that 
the term "RAS" represents not a single protein but three distinct genes (KRAS, NRAS and 
HRAS) and 4 distinct proteins (KRAS4A, KRAS4B, NRAS and HRAS) has directed 
attention to the roles of wild type RAS isoforms other than the mutated RAS allele (e.g., 
wild type KRAS in the presence of mutant NRAS). Third, amplification of RAS is being 
"rediscovered" as a potentially key cancer driver, along with the notion that gene dosage and 
protein expression levels have significant consequences that may differ at tumour initiation 
versus progression. Fourth, the increasing emphasis on cancer signaling as a complex 
network rather than as a series of partially connected linear pathways, and the continuing 
identification of new genetic aberrations via deep sequencing of patient tumours, have 
redirected attention to the critical role of RAS activity in cancers driven by the loss of 
negative regulators of RAS such as NF1 and other RAS GAPs, and the negative regulatory 
Sprouty (SPRY) family proteins.
1.1 RAS proteins are small GTPases that are deregulated in cancer
RAS proteins, the founding members of the RAS superfamily of small GTPases [1], are 
located at the center of a highly complicated signaling network that controls many aspects of 
fundamental normal cellular processes, including cell differentiation, survival and 
proliferation [2, 3]. RAS proteins are also key contributors to human oncogenesis [3–5]. In 
particular, point mutations that result in chronic activation of RAS are found in ~30% of all 
human cancers. Normally, RAS proteins are positively regulated by guanine nucleotide 
exchange factors (GEFs) such as SOS1 that facilitate exchange of GDP for GTP to promote 
the active state [6], and negatively regulated by GTPase activating proteins (GAPs) such as 
p120GAP and NF1 that catalyze hydrolysis of GTP back to GDP and thus promote 
restoration of the resting state [7]. Oncogenic mutations typically render RAS proteins 
relatively independent of the GEFs and/or insensitive to the GAPs that modulate the 
functions of wild type RAS. RAS activity can also be enhanced in cancers by amplification 
of oncogenic or wild type RAS and by escape of wild type RAS from regulation following 
gain of upstream inputs such as receptor tyrosine kinases (RTKs) or GEFs, or loss of 
downstream negative regulators such as GAPs or of feedback from SPRY/SPRED proteins.
1.2 RAS proteins exist as multiple isoforms
The human genome is home to three RAS genes (HRAS, NRAS, and KRAS), which 
together encode four RAS proteins (HRAS, NRAS, splice variants KRAS4A and KRAS4B). 
HRAS, located on chromosome 11, was the first isoform characterized in human cancers, 
and studies of this isoform dominated RAS research for many years [2]. The initial 
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underlying assumption was that RAS proteins are functionally redundant and thus 
interchangeable, which turned out to be an oversimplification that resulted in numerous 
wrong turns in the RAS field [4]. KRAS, residing on chromosome 12, encodes two splice 
variants at the 4th exon, KRAS4A and KRAS4B, the latter of which has long been regarded 
as the major isoform expressed in human cells. However, a recent study showed that 
KRAS4A can be expressed at levels comparable or near to that of KRAS4B [8], implying a 
need to consider both of these differentially regulated KRAS proteins. A third RAS isoform, 
not previously identified in any retrovirus studies, came to light a year after KRAS, and was 
designated NRAS (chromosome 1), because it was discovered in human neuroblastoma-
derived DNA [2]. These proteins share an overall 82–90% amino acid sequence identity, in 
which the regions required for nucleotide binding and effector interactions are essentially 
identical (Figure 1A). However, they differ significantly in the hypervariable region at their 
C-termini (Figure 1A), which are critical for their respective lipid modifications, and thus 
determine their distinct membrane binding and trafficking kinetics [9]. Each RAS isoform 
thus shares overlapping but distinct localizations at the plasma membrane and on 
endomembranes [10]. This allows RAS engagement of different pools of activators and 
effectors, contributing to isoform-specific signaling properties [11, 12].
1.3 RAS signaling pathways form a complex network subject to feedback regulation
RAS proteins transmit signals from a vast variety of inputs through numerous downstream 
effector pathways. The best-characterized of these, which have well-validated contributions 
to RAS pro-proliferation, -survival and -metastasis functions in cancer, are the canonical 
RAF-MEK-ERK and PI3K-AKT-mTOR kinase cascades, as well as the RAL-RALGEF and 
TIAM1-RAC small GTPase cascades [4, 5]. Detection of RAF-MEK-ERK and/or PI3K-
AKT-mTOR activity is often used as a surrogate for "RAS pathway activation" in cancers, 
whether or not they harbour mutant RAS. In addition, the RASSF family of tumour 
suppressors are RAS effectors that directly link RAS to pro-apoptotic pathways [13] as well 
as to a plethora of other functions important in cancer (see Donninger, Clark et al., this 
issue). These are not linear, independent pathways, but rather a complex network of 
interconnected, scaffolded nodes, with both positive and negative feedback loops. Key 
negative feedback mechanisms, such as the DUSP MAPK phosphatases and Sprouty 
negative regulators, are described in section 3.3.
1.4 RAS isoforms are functionally distinct
Although it has been challenging to reproducibly identify isoform- and mutation-dependent 
signaling differences directly in human tumours as has been done in model cell lines, 
typically by ectopic expression of mutant RAS [14–16], numerous studies have repeatedly 
demonstrated that RAS proteins are not all created equal [10, 17–23] (and many others). 
Although highly similar in structure, wild type RAS isoforms carry out overlapping but still 
very distinct functions [17, 20]. For example, genetic knockout studies in mice suggested 
that KRAS is the most important RAS isoform during development, since Kras-ablated mice 
die during embryogenesis [24, 25]. And although replacement of Hras into the Kras locus 
led to live births at the expected Mendelian ratio, the adult mice displayed cardiac 
abnormalities [26], indicating that HRAS was unable to completely replace KRAS function. 
In contrast, Nras gene function was shown to be dispensable for normal mouse development, 
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growth, and fertility [27], yet was later found to be important for antiviral immune response 
and T-cell function in mice [28]. Abrogration of Hras did not result in any developmental 
defects [29], but reduced the numbers of papillomas formed after 12-O-
tetradecanoylphorbol-13-acetate (TPA) treatment compared with wild type littermates [30]. 
Strikingly, Hras(−/−)/Nras(−/−) double knockout mice were viable, and displayed normal 
growth, fertility, and neuronal development [29]. Nevertheless, both wild type NRAS and 
KRAS were required for SV40 T Ag-induced transformation in mouse embryonic 
fibroblasts [18], during which they performed unique functions by engaging different 
signaling pathways. Specifically, wild type NRAS regulated cell adhesion through RAF and 
RhoA, whereas KRAS coordinated cell motility through AKT and Cdc42 [18].
1.5 RAS isoforms are oncogenically mutated and/or amplified in human cancers in distinct 
patterns
Among the evidence that the three RAS genes are distinct from each other are the biased 
frequency and distributions of RAS mutations in human cancers. Analysis of the COSMIC 
database (http://cancer.sanger.ac.uk/cosmic) shows (Figure 1B) that KRAS is by far the 
isoform most frequently mutated (85%) across human cancers. whereas NRAS is the second 
most frequently mutated (11%) and HRAS the least (4%). Another bias is the preferential 
mutation of a specific RAS isoform in a given tumour type [4]. For example, although rare 
in cancers overall, HRAS is the predominantly mutated isoform in bladder cancer (56% of 
all RAS mutations) and in head and neck squamous cell carcinoma (85%). NRAS, although 
rarely found in the pancreatic ductal adenocarcinomas or lung adenocarcinomas where 
KRAS mutations predominate (100% and 96%, respectively), is the major oncogenic RAS 
isoform in cutaneous melanoma (95%) and acute myeloid leukemia (59%). A third bias is 
the codon-specific mutation signature of each RAS isoform [31]. Most RAS mutations 
(98%) occur at the hotspots of codons G12, G13, or Q61 (Figure 1B). Thus, when KRAS is 
oncogenically mutated, both the KRAS4B and KRAS4A splice variant proteins expressed 
from the mutant allele are mutant. The vast majority (83%) of KRAS mutations occur at 
G12, whereas 63% of NRAS mutations occur at Q61 (Figure 1B). Yet Q61 mutations 
account for nearly 90% of all NRAS mutant cases of cutaneous melanoma, whereas G12 
mutations are more prominent in hematopoietic cancers. It is presently unknown whether the 
roles of wild type RAS proteins are related to particular RAS mutations, although there is 
some evidence that this may be the case [32, 33]; see section 2.1.1.
As discussed further in section 3.1, to induce and maintain a tumour, RAS activity must be 
optimally regulated so as to provide sufficient RAS signaling for transformation but not so 
much as to prompt oncogene-induced senescence [33–38]. Thus, RAS expression is 
sometimes differentially regulated by amplification, by mRNA stability, and even by altered 
translation due to codon bias [39]. As described in section 3.1, amplification of the wild type 
RAS isoforms is distinctly distributed across tumour types (cBioportal.org) [40, 41]. These 
observations are strong evidence for distinct functionalities of RAS isoforms and support the 
idea that wild type isoforms may also play distinct roles in RAS-mutant and RAS wild type 
cancers.
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2. Wild type RAS isoforms in RAS mutant cancers: tumour suppressors or 
tumour promoters?
The interplay between oncogenic and wild type RAS isoforms greatly affects tumour 
development and maintenance, and metastasis. Studies of wild type RAS can be divided into 
two broadly distinct categories: 1) those that assess the wild type counterpart of the 
oncogenic RAS isoform, and 2) those that assess the remaining two wild type RAS isoforms 
in the presence of the oncogenic isoform. The results of such studies have led to very distinct 
conclusions regarding the roles of wild type RAS isoforms in the context of mutant RAS, 
examples of which are shown in Figure 2.
2.1. Wild type alleles of the cognate mutant RAS isoform
Many mouse model carcinogenesis studies, in which cancers were initiated by chemical 
carcinogens or genotoxic insults that cause RAS mutations, identified loss of heterozygosity 
(LOH) resulting in loss of the cognate wild type Ras allele. LOH at Kras has frequently been 
observed in genetically engineered mouse models of mutant RAS-driven cancers. Likewise, 
RAS mutant human cancers often display LOH of the mutant RAS gene and loss of the wild 
type allele. These results suggest that the cognate wild type RAS serves a tumour 
suppressive function and must be lost in order for tumours to form and progress.
2.1.1 Evidence for a tumour suppressor function—Early studies of the functions of 
wild type RAS in transformation and oncogenesis focused on the wild type counterpart of 
the mutant isoform, and most concluded that wild type RAS plays tumour suppressive roles. 
For example, Spandidos and colleagues reported that transfection of the normal human H-
ras1 (HRAS) gene suppressed the transformed morphology and tumourigenic phenotypes of 
rat 208F fibroblasts transformed with the human T24 H-ras1 (HRAS) oncogene [42, 43]. 
Rarely, HRAS-transformed fibroblasts escaped suppression by wild type HRAS and 
eventually formed tumours in nude mice, but in these cases, wild type HRAS expression was 
markedly reduced. Balmain and colleagues also found loss of endogenous wild-type Hras at 
high frequencies in Hras mutant skin tumours induced by carcinogens [44], which induce 
distinct Ras mutations depending on the particular chemical insult [45]. Pellicer and 
colleagues observed that carcinogen-induced Nras-mutant thymic lymphomas undergo LOH 
at Nras and lack the wild type Nras allele [46], supporting a tumour suppressive role for wild 
type NRAS in the presence of mutant NRAS. Zhang and colleagues found that wild-type 
Kras2, the murine KRAS gene, suppressed the formation of chemically induced lung 
tumours that harboured Kras2 mutations [47]. Of note, this study utilized a Kras2+/− mouse 
model that harbours heterozygous loss of wild type KRAS. In an Nras−/− thymic lymphoma 
mouse model induced by the MNU carcinogen, which can provoke mutations in both Nras 
and Kras, loss of the wild type Kras allele was observed upon MNU-induced mutation of 
endogenous Kras, suggesting that loss of both wild type Nras and Kras isoforms more 
efficiently supported malignant transformation [48]. Further, adding back wild type Nras 
produced tumour suppressive effects whether or not oncogenic Nras was also added back 
[48]. More recently, Balmain and colleagues also reported tumour suppressive functions of 
wild type HRAS and KRAS in experimental models of HRAS-driven non-melanoma skin 
cancer and KRAS-driven lung cancer, respectively [49]. Surprisingly, wild type Kras4A was 
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identified as the main mediator of both the oncogenic activity of mutant KRAS and the 
suppressor activity of wild-type Kras [50]. Additionally, a role for wild type Kras gene 
dosage was uncovered in selecting the specific mutation induced by urethane. Wild type 
mice carried mostly Q61R Kras mutations, while those from Kras heterozygous mice carried 
mostly Q61L mutations [32]. In the same urethane-induced lung cancer model, Counter and 
colleagues found that optimizing codon usage of wild type Kras not only decreased the 
number of tumours but resulted in mutation switching from Q61R or Q61L to the weaker 
G12D [33]. It is interesting to speculate that these results imply differential effector 
utilization by these point mutants, whether at the level of specificity and/or efficiency, 
thereby requiring a greater or lesser degree of functional wild type RAS for tumour growth.
To test directly whether loss of the wild type RAS allele in spontaneous RAS mutant cancers 
is due to a tumour suppressor role of the wild type counterpart of oncogenic RAS, Bergö and 
colleagues used the Kras2LSLMx1-Cre (KM) mouse model to study Kras G12D induced 
leukemia. They found that expression of mutant Kras promoted proliferation and inhibited 
differentiation of early T-cell progenitors, but that all T-cell acute lymphoblastic leukemia 
(T-ALL) tumours identified in bone marrow-transplanted mice displayed loss of the wild 
type Kras2 allele as an obligate defect. Restoration of wild type KRAS (human KRAS4B) 
abolished the development of T-ALL but not myeloid proliferative neoplasms (MPN), 
further supporting a tumour suppressive role of wild type Kras in lymphoid cells [51]. In a 
related study of KrasG12D-induced leukemia, Zhang and colleagues found that genetic or 
epigenetic loss of wild type Kras expression promoted tumour growth and worse survival, 
although they observed preferential induction of MPN rather than T-ALL [52]. Consistent 
with this, they observed hyperactivation of cytokine signaling, e.g., through GM-CSF. 
Surprisingly, they also detected upregulation of RAS-GTP levels of each RAS isoform - 
including KRAS - upon loss of wild type KRAS, which occurred via gene deletion of the 
wild type allele. The mechanisms proposed in each of these studies to explain the differing 
results of the other with respect to myeloid versus lymphoid specificity likely cannot both be 
true simultaneously, but in any case, both studies revealed a tumour suppressive role for wild 
type Kras in KrasG12D-driven leukemias.
Whether wild type NRAS also has a tumour suppressor function in mutant NRAS-driven 
hematopoietic cancers, similar to that seen with wild type KRAS in mutant KRAS-driven 
cancers, is currently unclear. A study in an (endogenous locus) NrasG12D-driven model 
similar to the KM mice above, performed by Shannon and colleagues, revealed that loss of 
wild type Nras induced neither tumour suppressive nor tumour promoting activities [53], as 
described further in section 2.1.3. However, two different carcinogen-induced thymic 
lymphomas did display LOH of wild type Nras in the presence of Nras codon 61 mutations 
[46, 48]. In carcinogen-induced B-cell lymphomas, wild type Nras apparently served a 
tumour promoting function [54]; see section 2.1.2. Whether these differing results are due to 
distinct requirements for loss of wild type NRAS in different tumour types or in the context 
of G12 versus Q61 NRAS mutations, or due to some other factor(s), remains to be 
determined.
In addition to these mouse model studies, further evidence for a tumour suppressor function 
of wild type RAS in the context of the cognate mutant RAS isoform is provided by the 
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frequent findings of LOH and homozygously mutant RAS in established and patient-derived 
human cancer cell lines, patient-derived xenografts and primary tumours [55–58]. The 
implication is that allelic loss of the cognate wild type RAS is necessary for these tumours to 
become established and/or to progress. For example, as a followup to their study in 
chemically induced mouse lung cancers cited above [47], Li, Zhang, You and colleagues 
examined human lung adenocarcinomas and large cell lung cancers and found allelic loss of 
wild type KRAS in every tumour that harboured mutant KRAS [55]. In a comprehensive 
examination of 92 KRAS mutant cancer cell lines focusing on KRAS mutant pancreatic, 
lung and colon cancers, Gazdar and colleagues determined that mutant specific allelic 
imbalance (MASI) is both widespread and often accompanied by copy number gain (CNG) 
[58].
Finally, Su and colleagues created a new mouse model [56] that mimics the development 
and progression of human pancreatic ductal adenocarcinomas (PDA), a disease in which 
mutational activation of KRAS occurs with >95% frequency. KRAS mutation is one of the 
earliest events and is sufficient to cause the development of pancreatic intraepithelial 
neoplasia (PanINs), whereas progression to PDA requires additional mutations over time 
[59], such as loss of the tumour suppressors p16/Ink4A/Cdkn2a or p53. In human PDA, loss 
of p16/CDKN2A is the event next most frequent to KRAS mutation [60]. Accordingly, Su 
and colleagues generated a mouse model with tissue-specific conditional loss of p16 (but not 
p19/Arf) and mutational activation of KRAS (p16flox/flox;LSL-KrasG12D;Pdx1-Cre) that 
faithfully recapitulates development of PanIN, PDA and widespread metastasis [56]. They 
observed progressive LOH at Kras during the progression from PanIN to PDA to metastasis, 
such that only 3 of 17 representative cell lines derived from PDA metastases from these mice 
retained wild type Kras, whereas only 3 of 17 lines derived from primary tumours lacked it. 
The same LOH was observed in microdissected metastases. Further characterization showed 
that lines derived from primary tumours with LOH at Kras had more aggressively 
transformed phenotypes with respect to growth in low serum, wound healing migration 
ability, and anchorage-independent colony formation, supporting the idea that loss of wild 
type Kras enhances properties important for metastasis. Extending these studies to human 
cancer cell lines, whole-genome analyses showed LOH at KRAS (chromosome 12p) in 37% 
of lines derived from primary tumours and 80% of those derived from metastases. LOH was 
not found elsewhere, indicating that only wild type KRAS was lost, but not wild type NRAS 
or HRAS, and that loss of wild type KRAS was highly selected amongst other possible 
tumourigenic and metastasis-promoting alterations. Moreover, mutant KRAS was not 
amplified, indicating that loss of wild type KRAS was the primary alteration in KRAS 
abundance and the key reason for the functional differences observed. Collectively, these 
results strongly support a tumour suppressive role for wild type KRAS beyond initiation and 
extending to a role in metastasis suppression.
2.1.2 - Evidence for a tumour promoting function—Conversely, there is also 
evidence for a tumour promoting role of wild type RAS in the context of the cognate mutant 
RAS. By comparing signaling events in the isogenic pair of colorectal cancer cell lines 
HCT-116 (KRASG13D/WT) and Hke3 (KRAS−/WT) with or without siRNA-mediated 
silencing that selectively targeted wild type KRAS, Matallanas et al. demonstrated that 
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mutant KRAS activates the pro-apoptotic MST2 pathway, whereas wild type KRAS 
antagonizes this activation [61]. This indicates that, in these colorectal cancer cells, wild-
type KRAS supports rather than suppresses mutant KRAS-induced transformation. 
Collectively, while the vast majority of studies demonstrate a tumour suppressive role of the 
wild-type RAS allele in tumours driven by oncogenic activation of the cognate RAS 
isoform, it is also true that tissue and/or cellular specificity can influence the role that wild-
type RAS plays in tumours.
2.1.3 - Evidence that wild type RAS is neither tumour suppressive nor tumour 
promoting—Still other studies argue that wild type RAS does not necessarily always 
display either tumour suppressing or tumour promoting activities. In a mouse model of Nras-
driven AML, mutational activation of NrasG12D was insufficient to produce cancer, but 
required increased gene dosage of the activated allele (NrasG12D/NrasG12D) [53]. However, 
the loss of the wild type Nras allele in this homozygous mutant model was neither tumour 
suppressive nor tumour promoting, as ectopic expression of wild type NRAS or KRAS 
neither inhibited myeloid transformation by NrasG12D nor reduced the growth of progenitor 
cells expressing NrasG12D [53]. Additionally, despite somatic deletion of the wild type 
allele, expression of Nras was normal or elevated in AML blasts, a result of gene duplication 
of the oncogenic NrasG12D allele. Further, examination of human cancer cell lines in the 
Cancer Cell Line Encyclopedia [62] revealed that NRAS expression was elevated in NRAS-
mutant cancer cell lines compared to those lacking RAS mutations [53]. Collectively, these 
results suggest that loss of the wild type protein in these cancers is secondary to a need for 
increased dosage of oncogenic RAS rather than a need to lose a tumour suppressive function 
of wild type RAS.
2.2 Wild type alleles of the non-mutant RAS isoforms
Most of the studies that focused on wild-type RAS isoforms that are not the cognates of the 
oncogenically mutated isoform, but rather that are alleles of the non-mutant RAS isoforms 
(e.g., NRAS or HRAS in KRAS mutant cancers), have largely but not always revealed 
tumour promoting functions. For example, in a study aimed at understanding the mechanism 
of FTI (farnesyl transferase inhibitor)-mediated radiosensitization in cell lines that express 
oncogenic KRAS, wild type HRAS, although not wild type NRAS, contributed to radiation 
survival in most of the KRAS mutant pancreatic and colorectal carcinoma cell lines treated 
[63]. Similarly, ectopic expression of KRAS G12V in the colorectal cancer cell line Caco-2 
increased both the expression and activity of endogenous HRAS, and silencing of HRAS 
showed that oncogenic KRAS partly exerted its effects, such as enhanced invasiveness, 
through wild type HRAS [64]. On the other hand, Coffey and colleagues demonstrated that 
the presence of an oncogenic KRAS allele increased GTP-bound wild type NRAS in two 
human colorectal cancer cell lines, HCT116 and DLD-1, compared to their isogenic 
counterparts in which the mutant KRAS allele was disrupted by homologous recombination 
[65]. Although one might predict that this increased activation would enhance the anti-
apoptotic functions of wild type NRAS [66], they found instead that the presence of mutant 
KRAS sensitized the cells to apoptotic insults, possibly by altering the interactions of NRAS 
with gelsolin [65]. However, since the study did not include silencing or other disruption of 
Zhou et al. Page 8
Semin Cell Dev Biol. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the endogenous NRAS, it is not clear whether the altered NRAS:gelsolin interaction also 
impaired tumourigenicity.
A detailed mechanistic insight into how wild type isoforms might provide tumour promoting 
functions was first provided by Lim, Counter and colleagues, who showed that activation of 
eNOS (endothelial nitric oxide synthase) promotes C118 S-nitrosylation and activation of 
endogenous wild type HRAS and NRAS proteins in KRAS-mutant cells, suggesting that an 
oncogenic RASmut-PI3K–AKT-eNOS-RASWT pathway is required for both tumour 
initiation and maintenance [67]. Replacing C118, which is conserved among the RAS 
isoforms, with non-nitrosylatable C118S into wild type HRAS or NRAS inhibited xenograft 
tumour formation by KRAS-mutant human PDA cell lines, whereas the same C118S 
replacement into KRAS did not. This indicates that wild type but not oncogenic RAS 
proteins are the key target of eNOS in this context. The authors pointed out that activation of 
the other wild type RAS proteins by eNOS may thus serve as an important means to 
diversify RAS signaling beyond that of oncogenic RAS. In agreement with this speculation, 
they found that loss of wild type HRAS did not inhibit oncogenic HRASG12V-mediated 
oncogenesis in TtH cells expressing either scramble or HRAS shRNA in addition to RNAi-
resistant oncogenic HRASG12V. As indicated in section 2.1, the wild type counterparts of 
oncogenic RAS proteins are often lost in human cancers [55–58], suggesting that, in contrast 
to the non-counterpart wild-type isoforms, these play a tumour-suppressive role.
The interaction between oncogenic and wild type RAS proteins is the net result of a 
multitude of diverse mechanisms. Bar-Sagi and colleagues showed that oncogenic KRAS 
promotes allosteric stimulation of SOS, a key RAS GEF, and leads to activation of wild type 
HRAS and NRAS [68]. A later study then provided additional insights into RAS protein 
signaling networks [69], in which wild type HRAS or NRAS depletion from KRAS mutant 
cancer cells hyperactivated both ERK-p90 RSK and PI3K-AKT, leading to inhibitory 
phosphorylation of Chk1 at S280. The resulting inhibition of the G2 DNA damage 
checkpoint then led to increased sensitivity of KRAS mutant cells to DNA damaging agents 
such as the topoisomerase I inhibitor irinotecan. Furthermore, oncogenic and wild type RAS 
isoforms have been reported to be responsible for regulating different aspects of signal 
transduction, with McCormick and colleagues reporting that oncogenic RAS modulates 
basal mitogen-activated protein kinase (MAPK) pathway signaling, and wild type isoforms 
control response to stimulatory growth factor signaling [70].
There are some slim observations that demonstrate a potential need for wild type RAS in 
NRAS mutant cancer cells. A cell proliferation defect was seen in the NRAS mutant 
rhabdomyosarcoma cell line RD (NRASQ61H) upon knockdown of wild type HRAS and/or 
KRAS [70]. In the melanoma cell line SK-MEL-103 (NRASQ61R), knockdown of wild type 
HRAS enhanced γH2AX levels, indicating DNA damage regulation by wild type HRAS 
[69]. However, surprisingly little is known about whether NRAS mutant cancers require wild 
type KRAS or HRAS for tumour initiation and/or maintenance. Our ongoing studies 
(manuscript in preparation) indicate that at least NRAS mutant melanomas require the wild 
type versions of both of the other RAS isoforms for full transforming activity.
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3. Contribution of wild type RAS to RAS wild type cancers
In some mouse model chemical carcinogenesis studies, gastric or hepatic cancers were 
promoted by overexpression of wild type Hras in the absence of mutated Ras [71, 72]. 
Likewise, chemically induced B cell lymphomas were promoted by overexpression of wild 
type Nras [54]. These results, along with a plethora of studies in which ectopic expression of 
wild type human RAS isoforms was sufficient to transform rodent fibroblasts to 
tumourigenicity [2, 3, 5], suggested that overexpression of wild type RAS alone could be 
sufficient to promote tumourigenicity, albeit with the caveat that too much RAS leads to 
arrest and senescence. More compellingly, endogenous wild type RAS proteins have been 
demonstrated to contribute by multiple mechanisms to tumour initiation, progression and 
maintenance, as well as to metastasis, of human cancer cell lines and patient tumours.
3.1 Amplification of wild type RAS
In most cancer types where RAS is altered oncogenically in some way, analysis of the 
TCGA data indicates that the vast majority of alterations are somatic missense mutations 
that increase RAS activation (cBioPortal.org) [40, 41]. However, in some cases, there is 
amplification of wild type RAS along with oncogenic RAS mutation. For example, in NRAS 
mutant melanoma, NRAS amplifications can co-occur in tumours with NRAS mutations 
[73]. In rare cases, for example in neuroendocrine prostate cancer, a third of all samples 
examined displayed amplification of RAS but not mutations [73], and in some of these 
cases, more than one wild type RAS isoform was amplified (cBioPortal.org) [40, 41]. 
Examples of other tumour types where amplification of wild type RAS but not missense 
mutation is frequently seen include ovarian serous cystadenocarcinoma [74] and esophageal 
carcinoma.
3.2 Activation of wild type RAS by gene fusion
RAS mutations are uncommon in prostate cancer [73] despite high levels of RAS pathway 
activity. Instead, a common mechanism for upregulation of RAS activity is epigenetic loss of 
the RASGAP DAB2IP [75]; see section 3.3.1. In addition, a rare but completely distinct 
mechanism of RAS activation has been identified recently. Nearly 50% of prostate cancers 
harbour gene rearrangements of androgen-driven genes with ETS family transcription 
factors [76]. Upon searching for additional driver gene fusion events in a panel of prostate 
adenocarcinoma cell lines, Chinnaiyan and colleagues uncovered a novel gene 
rearrangement of KRAS in DU145 cells [77]. The ubiquitin-conjugating enzyme UBE2L3 
was fused to full length KRAS, generating a UBE2L3-KRAS fusion protein that was 
ubiquitinated and relatively unstable, yet fully capable of transforming NIH 3T3 mouse 
fibroblasts. Examination of 62 metastatic prostate carcinomas identified the same fusion in 2 
patient tumours [77], thereby validating that this rearrangement, although rare, is also found 
in clinical specimens of prostate cancer. Whether such RAS-activating fusion proteins are 
also present in other tumour types, and the precise nature of their contributions to 
oncogenesis, tumour maintenance and metastasis, have yet to be determined.
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3.3 Activation of wild type RAS by loss of negative regulators
Two major mechanisms for negative regulation of RAS activity act either directly at the level 
of RAS itself (RAS GAPs) or indirectly by negative feedback on RAS activators 
(SPROUTY and SPRED proteins).
3.3.1 Activation of wild type RAS by loss or suppression of RAS GAPs—RAS 
GAPs promote hydrolysis of RAS-GTP to RAS-GDP, thereby restoring the resting, inactive 
state of RAS proteins. It is increasingly appreciated that loss of RAS GAPs is important in 
cancers driven by RAS pathway activation in the absence of mutations in RAS itself. Of the 
14 RAS GAPs identified to date, NF1, RASAL1, RASAL2 and DAB2IP perform critical 
tumour suppressor functions via their roles in downregulating RAS activity [7, 78, 79].
In particular, the product of the NF1 gene, neurofibromin, is not only involved in the familial 
cancer syndrome neurofibromatosis type 1 (NF1) through germline mutation, but is also 
involved in many types of sporadic cancers through somatic mutation. For example, NF1 
loss-of-function mutations are commonly seen in melanomas [80], glioblastomas [81, 82], 
and lung adenocarcinomas [83] and squamous cell carcinomas [84]. These are largely not 
co-occurrent with RAS mutations, suggesting that the pathways are generally redundant. 
The co-occurrence of NF1 loss in NRAS-mutant melanoma may be explained by the 
surprising consequence of activation of wild type KRAS and HRAS, but not NRAS [85] in 
this tumour type, although this selectivity is not always seen [86]. Loss of NF1 has also been 
shown to promote resistance to RAS pathway inhibitors by enhancing ERK signaling, and 
has been validated as a potential mechanism of intrinsic resistance in cell culture as well as 
of acquired resistance in patient tumour samples [85–87].
DAB2IP is a tumour suppressor of many aggressive cancers, where it is downregulated 
epigenetically by the histone methyltransferase EZH2 [75], and at the protein level by AKT-
SCFBW7-SMURF1 [88]. A large signaling scaffold protein (1189 amino acids), DAB2IP 
(also known as ASK-interacting protein and by other names) forms part of several 
cytoplasmic signaling complexes that enable it to modulate numerous signaling pathways 
that control responses to growth factor signaling, stress, and apoptosis. In addition to its 
RAS GAP activity, DAB2IP also modulates RAS signaling via its interaction with RALBP1 
and other components. In cancers that lack RAS mutations, such as prostate, breast, 
medulloblastoma, and others, DAB2IP is frequently lost. Cichowski and colleagues 
demonstrated that, in prostate cancer, loss of DAB2IP results in separate modes of activation 
of RAS and NF-κB, thereby separately promoting tumour growth and metastasis, 
respectively [75].
3.3.2 DUSPs, SPROUTY/SPRED—In addition to forward propagation, RAS pathway 
signaling is also regulated by numerous levels of feedback phosphorylation to provide 
sensitive and temporal modulation and to restrict signaling output. For example, activation 
of ERK1/2 induces transcriptional upregulation of negative regulators, including dual-
specificity MAP kinase (MAPK) phosphatases (MKPs or DUSPs) and Sprouty (SPRY) 
proteins. ERK1/2 signaling drives the expression of a variety of DUSP proteins, including 
the ERK-specific phosphatases DUSP5 (nuclear) and DUSP6/MKP3 (cytoplasmic) [89, 90], 
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thus providing a straightforward means of controlling its own activity. The importance of 
DUSPs in controlling RAF-MEK-ERK signaling in cancer is exemplified by the frequent 
loss of DUSP6 in EGFR- and KRAS-driven non-small cell lung cancers [90] and by the 
finding that loss of DUSP5 accelerates HRAS-driven skin cancer in mice [91].
SPRY proteins also act as negative regulators of RTK-RAS-RAF-MEK-ERK signaling [92, 
93]. Growth factor stimulation leads to tyrosine phosphorylation and plasma membrane 
translocation of SPRY1 and SPRY2, where they bind the adaptor protein Grb2 to prevent 
recruitment of the Grb2-SOS complex that couples growth factor stimulation to RAS 
activation [92]. Loss of SPRY proteins can promote several types of cancer in combination 
with either the presence of other oncogenes or loss of other tumour suppressors. For 
example, loss of SPRY1 and SPRY2 in prostatic epithelium hyperactivates RAS-MAPK 
signaling and, along with loss of the tumour suppressor PTEN, promotes prostatic 
adenocarcinoma in this RAS wild type cancer [94]. Combined loss of SPRY4, NF1 and p53 
promotes acute myeloid leukemias in the absence of KRAS or NRAS (or FLT3 or KIT) 
mutations [95]. Combined loss of SPRY4 and NF1 would be predicted to upregulate RAS 
activity, with loss of p53 required to avert oncogene-induced senescence [34]. Although 
RAS-GTP levels were not evaluated in this study, RAS pathway activation was clearly 
upregulated, as demonstrated by increased phospho-ERK and phospho-S6 levels [95]. 
Understanding the negative feedback that occurs or is lost upon downregulation of these 
regulators of RAS activity is important for predicting the consequences of 
pharmacologically inhibiting elements of this pathway for cancer treatment, as well as for 
unraveling the consequences of signaling from wild type RAS isoforms in the presence of 
oncogenic RAS.
3.4 Activation of wild type RAS by upregulation of positive regulators
Upregulation of positive regulators including increased signaling from overexpressed or 
oncogenically mutated receptor tyrosine kinases such as EGFR, FGFR, IGF1R, etc. (Figure 
3), can also result in increased RAS signaling, often via the best characterized RAS GEF, 
SOS1. This has been an attractive target of investigation as a node of RAS inhibition through 
blocking the RAS-SOS1 interaction [4]. However, SOS1 mutations are generally rare in 
human cancers [96], and are even less frequent in wild-type RAS tumours. Instead, wild 
type RAS is more frequently activated by upstream mechanisms that transmit signals 
through SOS1, such as in EGFR-mutated or ALK-translocated lung adenocarcinoma [83]. 
Aberrant upregulation of the RAS GEF RASGRP1 has been strongly implicated in T-cell 
leukemogenesis, due to its predominant expression in these cells [97]. Overexpression of 
RASGRP1 alone is capable of inducing T-cell acute lymphoblastic leukemia (T-ALL) in 
both murine models and pediatric patients [97]. RASGRP1-overexpressing T-ALL exhibits 
constitutively high RAS-GTP, mechanistically distinguishing it from KRASG12D-driven T-
ALL that lacks constitutive GTP loading of RAS. Kitamura and colleagues showed that 
aberrantly expressed RASGRP1 cooperated with frequent secondary NOTCH1 gain-of-
function mutations to promote mouse T-ALL [98].
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4. Concluding remarks
Wild type RAS plays critical roles in both RAS mutant and RAS wild type cancers, in a 
context-dependent manner. The wild type KRAS isoform largely acts as a tumour suppressor 
in the context of the cognate mutant KRAS isoform, and its loss facilitates initation and 
progression as well as metastasis. Support for similar roles of the wild type NRAS isoform 
in NRAS-driven cancers is more mixed. Some emerging evidence shows that the other wild 
type RAS isoforms, HRAS and NRAS, may not only be tolerated but even act as tumour 
promoters of mutant KRAS. The activity of wild type RAS isoforms is also aberrantly 
upregulated by amplification and by loss of negative RAS regulators such as the DUSP 
MAPK phosphatases and of NF1 and other RAS GAPs, and by overexpression of positive 
regulatory GEFs. Ongoing investigations of the contribution of wild type RAS in cancer will 
certainly reveal additional complexities, some of which may uncover vulnerabilities 
amenable to cancer treatment.
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Figure 1. RAS isoforms
A. Sequence identity and divergence between the four human RAS proteins include 
conformational changes to the switch I (SI; amino acids 30–38) and II (SII; 59–76) regions 
in the GDP and GTP bound states, hence regulating effector binding affinity. G domain, 
GTP-binding. HVR, hypervariable region. CAAX, Cysteine, Aliphatic, Aliphatic, Any 
amino acid. Sites of posttranslational modifications are indicated by underlines and boxes; P, 
phosphorylation. B. Frequency of missense mutations in the three human RAS genes and at 
the three hotspots for RAS mutations (codons G12, G13 and Q61).
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Figure 2. Interplay between wild type and mutant RAS alleles in cancer
(A) Wild type RAS proteins can display either tumour promoting or tumour suppressing 
functions, depending on context. Some ways in which mutant KRAS promotes 
tumourigenesis are by (B) allosteric activation of the RAS GEF SOS1 to activate wild type 
HRAS and NRAS, or (C) activation of eNOS (endothelial nitric oxide synthase) to 
nitrosylate and activate wild type HRAS. Additionally (D), wild type HRAS and NRAS can 
block inhibition of the G2 DNA damage checkpoint to promote genome maintenance.
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Figure 3. Mutational activation of the RAS signaling network in cancer
RAS function can be activated directly by mutation of RAS or indirectly by mutational 
activation or loss of components upstream or downstream of RAS. Missense mutation 
frequencies are indicated in parentheses and were compiled from COSMIC.
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